Login to Your Account



Amgen, Daiichi Sankyo ink 9-product biosimilar deal in Japanese market

By Cornelia Zou
Staff Writer

Friday, July 15, 2016

HONG KONG – Japan could welcome nine biosimilar drugs to the market in the coming years, thanks to a commercialization deal between Amgen Inc. and local company Daiichi Sankyo Co. Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription